Viking Therapeutics Prices Upsized $500 Million Stock, Convertible Notes Offering

Voyager Therapeutics (VYGR) named Robin Swartz, its current chief business and operating officer, as president effective October 20, 2026. Swartz is expected to succeed Alfred Sandrock Jr. as CEO in early 2027, pending safety data from a clinical trial. The transition plan was announced by the company.

Voyager Therapeutics (VYGR) appointed Robin Swartz as President, effective Oct. 20, 2026, and expects her to succeed Alfred W. Sandrock as CEO in Q1 2027. The transition is pending the enrollment and initial safety data for VY1706. Sandrock is expected to join the Board after the transition.

Viking Therapeutics raised ~$547.8M in net proceeds from a $575M offering of common stock and convertible notes. The offering included 9,035,714 shares at $35.00 each and $258.75M in notes due 2032. Underwriters exercised options for additional shares and notes.

Voyager Technologies' shares dropped 7.8% in after-hours trading after announcing a $350 million convertible senior notes offering. The company plans to use proceeds for capped call transactions, general corporate purposes, and expansion. Shares closed at $37.53, up 44% year-to-date.

Viking Therapeutics' shares rose 29.69% to $39.05 after reporting positive trial results for its obesity drug VK2735, showing significant weight loss retention on reduced dosing. The trial demonstrated 97% and 90% retention for every-other-week and monthly dosing, respectively, compared to 61% for placebo. The company is advancing both injectable and oral formulations of VK2735 through Phase 3 trials.

Viking Therapeutics' stock rose 26% after positive data on its weight-loss drug, VK2735, which maintained up to 97% of prior weight loss. Roche also released study results for its obesity drug, but its shares saw little movement. Viking is seen as a potential acquisition target. The data highlights the importance of weight maintenance in obesity treatments.